271 related articles for article (PubMed ID: 25717269)
1. Hepatitis B reactivation and timing for prophylaxis.
Tuna N; Karabay O
World J Gastroenterol; 2015 Feb; 21(7):2263-4. PubMed ID: 25717269
[TBL] [Abstract][Full Text] [Related]
2. Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.
Gozdas HT; Arpaci E
World J Gastroenterol; 2015 Sep; 21(35):10251-2. PubMed ID: 26401092
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
5. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
[No Abstract] [Full Text] [Related]
6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
7. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
10. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
Liu CY; Chandrasekar PH; Masood A; Schiffer CA
J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
12. Reply to S. Kusumoto et al.
Huang YH; Lin HC; Lee SD
J Clin Oncol; 2013 Dec; 31(35):4481. PubMed ID: 24220562
[No Abstract] [Full Text] [Related]
13. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
Buensalido JA; Chandrasekar PH
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
[TBL] [Abstract][Full Text] [Related]
14. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
16. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues.
Yağci M; Acar K; Sucak GT; Aki Z; Bozdayi G; Haznedar R
Leuk Lymphoma; 2006 Aug; 47(8):1608-12. PubMed ID: 16966273
[TBL] [Abstract][Full Text] [Related]
17. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
19. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
Zhang HY; Liu ZG; Zhang Z; Gong HY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):459-62. PubMed ID: 20819491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
